The Novel Collagen Matrikine, Endotrophin, is Associated with Mortality and Cardiovascular Events in Patients with Atherosclerosis by Nielsen, Signe Holm et al.
                                                                    
University of Dundee
The Novel Collagen Matrikine, Endotrophin, is Associated with Mortality and
Cardiovascular Events in Patients with Atherosclerosis
Nielsen, Signe Holm; Edsfeldt, Andreas; Tengryd, Christoffer; Gustafsson, Hilda; Shore,
Angela C.; Natali, Andrea
Published in:






Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Nielsen, S. H., Edsfeldt, A., Tengryd, C., Gustafsson, H., Shore, A. C., Natali, A., Khan, F., Genovese, F.,
Bengtsson, E., Karsdal, M., Leeming, D. J., Nilsson, J., & Goncalves, I. (2021). The Novel Collagen Matrikine,
Endotrophin, is Associated with Mortality and Cardiovascular Events in Patients with Atherosclerosis. Journal of
Internal Medicine. https://doi.org/10.1111/joim.13253
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 29. May. 2021
doi: 10.1111/joim.13253
The novel collagen matrikine, endotrophin, is associated
with mortality and cardiovascular events in patients with
atherosclerosis
S. Holm Nielsen1,2,† , A. Edsfeldt3,4,5,† , C. Tengryd4, H. Gustafsson4, A. C. Shore6, A. Natali7, F. Khan8,
F. Genovese1, E. Bengtsson4 , M. Karsdal1, D. J. Leeming1, J. Nilsson4 & I. Goncalves3,4
From the 1Nordic Bioscience, Herlev; 2Department of Biomedicine and Biotechnology, Technical University of Denmark, Lyngby, Denmark;
3Department of Cardiology, Skane University Hospital; 4Department of Clinical Sciences; 5Wallenberg Center for Molecular Medicine, Lund
University, Malm€o, Sweden; 6Diabetes and Vascular Medicine, University of Exeter, Medical School, National Institute for Health Research
Exeter Clinical Research Facility, Exeter, UK; 7Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; and 8Division
of Molecular and Clinical medicine, University of Dundee, Dundee, UK
Abstract. Holm Nielsen S, Edsfeldt A, Tengryd C,
Gustafsson H, Shore AC, Natali A, Khan F,
Genovese F, Bengtsson E, Karsdal M, Leeming
DJ, Nilsson J, Goncalves I (Nordic Bioscience,
Biomarkers and Research, Herlev; Skane
University Hospital, Malm€o; Lund University,
Malm€o; Lund University, Malm€o, Sweden; Medical
School, National Institute for Health Research
Exeter Clinical Research Facility, Exeter, UK;
University of Pisa, Pisa, Italy; and University of
Dundee, Dundee, UK). The novel collagen
matrikine, endotrophin, is associated with
mortality and cardiovascular events in patients
with atherosclerosis (Original article). J Intern Med
2021; https://doi.org/10.1111/joim.13253
Background. Rupture of atherosclerotic plaques is the
major cause of acute cardiovascular events. The
biomarker PRO-C6 measuring Endotrophin, a
matrikine of collagen type VI, may provide valuable
information detecting subjects in need of intensi-
fied strategies for secondary prevention.
Objective. In this study, we evaluate endotrophin in
humanatheroscleroticplaquesandcirculating levels
of PRO-C6 in patients with atherosclerosis, to deter-
mine the predictive potential of the biomarker.
Methods. Sections from the stenotic human carotid
plaques were stained with the PRO-C6 antibody.
PRO-C6 was measured in serum of patients
enrolled in the Carotid Plaque Imagining Project
(CPIP) (discovery cohort, n = 577) and the innova-
tive medicines initiative surrogate markers for
micro- and macrovascular hard end-points for
innovative diabetes tools (IMI-SUMMIT, validation
cohort, n = 1,378). Median follow-up was
43 months. Kaplan–Meier curves and log-rank
tests were performed in the discovery cohort. Cox
proportional hazard regression analysis (HR with
95% CI) was used in the discovery cohort and
binary logistic regression (OR with 95% CI) in the
validation cohort.
Results. PRO-C6 was localized in the core and
shoulder of the atherosclerotic plaque. In the
discovery cohort, PRO-C6 independently predicted
future cardiovascular events (HR 1.089 [95% CI
1.019 1.164], p = 0.01), cardiovascular death
(HR 1.118 [95% CI 1.008 1.241], p = 0.04) and
all-cause death (HR 1.087 [95% CI 1.008 1.172],
p = 0.03). In the validation cohort, PRO-C6 pre-
dicted future cardiovascular events (OR 1.063
[95% CI 1.011 1.117], p = 0.017).
Conclusion. PRO-C6 is present in the atherosclerotic
plaque and associated with future cardiovascular
events, cardiovascular death and all-cause mortal-
ity in two large prospective cohorts.
Keywords: atherosclerosis, biomarkers, collagen, en-
dotrophin, extracellular matrix, inflammation.
Abbreviations: ECM, extracellular matrix; MMP-11,
matrix metalloproteinase-11; CPIP, Carotid Plaque
Imaging Project; IMI-SUMMIT, innovative medici-
nes initiative surrogate markers for micro- and
macrovascular hard end-points for innovative dia-
betes tools; CRP, C-reactive protein; LDL, low-
density lipoprotein; HDL, high-density lipoprotein.
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Introduction
Despite recent advancements in treatments for
atherosclerotic diseases, the clinical consequences
of stroke and myocardial infarction are still the
major causes of mortality and morbidity worldwide
[1]. There is a need for novel biomarkers which may
reflect plaque vulnerability and the risk for recur-
rent events, and which may help the design of
individually tailored treatment strategies [2].
The rupture of an atherosclerotic plaque is the
major cause of acute cardiovascular events. These
events tend to occur in patients with vulnerable
plaques, of the rupture-prone type, which have a
large lipid-rich core, a thin fibrous cap and an
increased inflammatory cell infiltration [3, 4]. A
thin fibrous cap is the result of degradation of ECM
proteins, especially the main structural ECM pro-
teins, collagen type I, III and VI, which are in the
major constituents of the fibrous cap [5]. Collagen
integrity is therefore a critical determinant of
plaque stability, and disturbed collagen remod-
elling is a potential marker of plaque vulnerability.
Collagen type VI is a beaded filament produced by
fibroblasts and is expressed in the atherosclerotic
plaque [5]. It is localized in the interface between
the interstitial matrix and the basement mem-
brane, where it forms an intricate mesh of
microfilaments [6]. Collagen type VI is a hetero-
trimer composed by the combination of six differ-
ent a-chains (a1-a6), where the C5 domain of the a3
chain has been shown to be important for microfib-
ril formation (Fig. 1) [7]. The C5 domain contains a
Kunitz-type domain which constitutes the matri-
kine Endotrophin (Fig. 1) [8]. According to a study
by Motrescu et al, the C5 domain of collagen type
VI is a potential substrate for matrix metallopro-
teinase-11 (MMP-11) cleavage [9]. Endotrophin is a
bioactive molecule which increases TGF-b expres-
sion by the attraction of macrophages, promoting
adipose tissue fibrosis and metabolic dysfunction
[8]. The marker PRO-C6 corresponds to the C-
terminal of the C5 domain which is cleaved off after
secretion from the cell, thereby reflecting both
collagen type VI extracellular formation and
released Endotrophin [10].
The expression of PRO-C6 in atherosclerotic pla-
ques or the role of PRO-C6 in predicting cardio-
vascular events, cardiovascular death and all-
cause death in atherosclerosis patients has not
previously been explored.
In this study, PRO-C6 was detected with immuno-
histochemistry in advanced human carotid
atherosclerotic plaques and serum PROC-6 levels
were analysed in two clinical cohorts: the Carotid
Plaque Imaging Project (CPIP) and the innovative
Fig. 1 Structure of collagen type Via3-chain and release of the pro-peptide from the a3-chain. Collagen type VI forms
polymers intracellulary before secretion into the ECM. The C5 domain of the a3 chain is immediately cleaved off from the
mature collagen type VI tetramer after secretion. The Figure is modified with permission from Karsdal et al. 2019.
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medicines initiative surrogate markers for micro-
and macrovascular hard end-points for innovative
diabetes tools (IMI-SUMMIT).
Methods
A more detailed method description can be found
in the online supplementary material.
Immunohistochemistry
Paraffin sections (6 lm) of the most stenotic part of
the human carotid plaques from the discovery cohort
(CPIP) were fixed in formalin and used for immuno-
histochemistry. To stain for PRO-C6, a monoclonal
antibody was used (Nordic Bioscience, Herlev, Den-
mark) diluted 1:12,000 (0.65 lg/ml). Nuclei counter-
stainingwasperformedwithMayer’shaematoxylin. A
monoclonalmouse isotype control (ab81032, Abcam,
Cambridge, UK) was used in a concentration corre-
sponding to the primary antibody (0.67 lg/ml).
Scanning of the stained slides was performed with
Aperio ImageScope (version 12.3.2.8013).
Cohorts
The discovery cohort included 577 patients from
the Carotid Plaque Imaging Project (CPIP) cohort,
Clinical Research Center (CRC), Lund University,
Malm€o, Sweden. The validation cohort consisted of
1378 patients from the IMI-SUMMIT cohort
recruited from four different European sites (Dun-
dee, Pisa, Malm€o and Exeter University Hospitals).
The IMI-SUMMIT cohort was constructed to study
the therapeutic need for new treatments of diabetes
complications, such as cardiovascular disease. The
cohort was designed to study novel biomarkers
that can be used for preclinical and clinical trials
and thereby accelerate the drug development.
Demographic and clinical data, as well as blood
samples, were obtained from both cohorts. Addi-
tionally, human carotid atherosclerotic plaque tis-
sue was obtained from the discovery cohort (CPIP).
The clinical characteristics of the discovery and
validation cohort are shown in Table 1.
Discovery cohort - CPIP
Fivehundredandseventy-sevenpatientswhounder-
went carotid endarterectomyat theVascularDepart-
ment at Skane University Hospital (Malm€o, Sweden)
between 2005 and 2017 participated in the study.
Indications for surgery were ipsilateral symptoms
(amaurosis fugax, transitory ischaemic attack or
stroke) along with a degree of stenosis > 70%. Sur-
gical indications for asymptomatic patients were
stenosis > 80%. Eight of the patients were included
on two occasions as they underwent surgery at two
occasions. All patients were assessed by a neurolo-
gist preoperatively. Clinical data and cardiovascular
risk factors such as age, hypertension, smoking,
obesity, statins and family history of cardiovascular
events were recorded in a patient survey at time of
inclusion. Blood levels of C-reactive protein (CRP),
low-density lipoprotein (LDL), high-density lipopro-
tein (HDL), triglyceridesandcreatininewereobtained
frommedical charts. The carotid plaques were taken
from surgery, snap-frozen in liquid nitrogen and
stored at 80°C. Serum samples were collected
24 hours before surgery and processed immediately
according to standard protocols. Informed consent
was givenbyall patients, and the studywas accepted
by the local ethics committee (472/2005).
Validation cohort – IMI-SUMMIT
The IMI-SUMMIT study cohort was used as a vali-
dation cohort. This study included four groups:
patients with type 2 diabetes (T2D) and cardiovas-
cular disease (CVD), patients with T2D and no CVD,
patients with CVD but no diabetes and patients
without diabetes or CVD. Exclusion criteria
included renal replacement therapy, malignancy
requiring active treatment, end-stage renal disease,
any chronic inflammatory disease on therapy, pre-
vious bilateral carotid artery invasive interventions
or atrial fibrillation. Demographics and clinical
characteristics, including medication and physical
and laboratory examinations, were obtained
according to a predefined study protocol at all four
participating centres. The variable previous CVD
included nonfatal acute myocardial infarction, hos-
pitalized unstable angina, resuscitated cardiac
arrest, any coronary revascularization procedure,
nonfatal stroke, transient ischaemic attack con-
firmedbya specialist, lower extremity artery disease
defined as an ankle-brachial pressure index (ABPI),
less than 0.9with intermittent claudication, or prior
corrective surgery, angioplasty or above-ankle
amputation. Diabetes was defined based on con-
temporary or historical evidence of hyperglycaemia
(according to World Health Organization 1998 cri-
teria; fasting plasma glucose 7.0 mmol/L or 2-h
plasma glucose 11.1 mmol/L, or both) or by current
medication with insulin, sulphonylureas, met-
formin or other antidiabetic drugs. Obesity was
defined as a BMI above 30. The patients were
enrolled at four European University Hospitals
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(Malm€o, Lund University in Sweden, n = 399; Dun-
dee University in UK, n = 369; Exeter University in
UK, n = 308; and Pisa University in Italy, n = 302)
between 2010 and 2013. Informed consent was
given by all patients, and the study was accepted by
the local ethical committee (2010/464).
Discovery cohort (CPIP) follow-up
Follow-up data from the discovery cohort were
available for 433 (75% of cohort) patients until
2015-12-31. The operated patients were followed
for a median of 43 months. Telephone interviews
with patients, medical charts and the Swedish
National Patient Register were sources of follow-up
information. Patients operated bilaterally were only
followed up regarding their first surgery.
Cardiovascular events included myocardial infarc-
tions, unstable angina, strokes, transient ischae-
mic attack, amaurosis fugax and any vascular
interventions not planned at the time of the oper-
ation such as carotid endarterectomy, carotid
artery stenting, coronary artery bypass grafting or
percutaneous coronary artery intervention, and all
deaths with an underlying cardiovascular cause of
death. Events or deaths occurring within 72 hours
after the endarterectomy were considered proce-
dure-related and were excluded from the analysis.
Events were obtained from the Swedish National
Patient Register based upon discharge codes from
hospitalization of the patients. The ICD codes used
to define cardiovascular events and cardiovascular
death can be found in the online supplemental
material.
Validation cohort (IMI-SUMMIT) follow-up
Patients in the validation IMI-SUMMIT cohort were
routinely followed up with a new visit after
36 months, and complete follow-up data were
available for 1319 patients (96%). Complete




(n = 1378) p-value
Median PRO-C6 (ng/ml) 7.9 (5.4–10.3) 8.9 (7.2–11.4) 2.93 9 1015
Age (years) 72 (66–78) 68 (62–74) 6.66 9 1021
Male (%) 365 (63) 909 (66) ns
Height (cm, IQR) 171 (164–177) 170 (164–176) ns
Weight (kg, IQR) 78 (68–88) 84 (74–94) 4.01 9 1016
BMI (IQR) 26.4 (24.0–29.3) 28.6 (25.7–32.3) 4.14 9 1025
Waist (cm, IQR) 99 (91–106) 103 (94–111) 3.36 9 109
Diabetes (%) 132 (23) 917 (66) 3.13 9 1072
Hypertension (%) 437 (76) 924 (67) 1.25 9 104
Obesity (%) 119 (21) 539 (33) 3.55 9 1018
Statins (%) 523 (91) 915 (67) 2.95 9 1031
Current smoking (%) 190 (33) 146 (11) 4.66 9 1030
Blood samples
Creatinine (µmol/L) 85 (72–104) 81 (70–93) 4.00 9 106
CRP (mg/L) 2.7 (1.2–7.0) 1.4 (0.7–3.0) 1.19 9 1023
Total Cholesterol (mmol/L) 4.3 (3.6–5.4) 4.2 (3.6–5.0) 0.04
Triglycerides (mmol/L) 1.3 (1.0–1.7) 1.3 (1.0–1.9) 0.018
LDL (mmol/L) 2.6 (1.9–3.5) 2.3 (1.8–3.0) 3.89 9 108
HDL (mmol/L) 1.2 (1.0–1.5) 1.3 (1.0–1.5) 4.00 9 105
HbA1c (mmol/mol)a 41 (37–48) 48 (40–59) 5.55 9 1018
Values are median, interquartile range (IQR) or n (%). For comparison between the discovery cohort and the validation
cohort, Mann–Whitney U-tests were used for continuous variables and chi-square tests were used for categorical
variables. p < 0.05 were considered significant.
aHbA1c only for subjects with diabetes in the discovery cohort (CPIP).
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follow-up data were missing for 59 patients (4.3%)
which were not included in the follow-up analysis.
Three end-points were recorded as follows: all-
cause death, cardiovascular death and cardiovas-
cular events. Cardiovascular events included any
fatal or nonfatal cardiovascular events and
included all diagnoses used to define cardiovascu-
lar disease at baseline described above. The time to
events variable was not registered in this study.
Therefore, it was not possible to perform Cox
proportional hazard regression analysis as in the
discovery cohort.
Biomarker measurements
Serum samples from 557 patients from the discov-
ery cohort and 1378 EDTA plasma samples from
the validation cohort were available for measure-
ment of PRO-C6. PRO-C6 was measured by a
competitive ELISA developed at Nordic Bioscience
(Herlev, Denmark). The monoclonal antibody
employed in the ELISA assay was raised against
the last 10 amino acids of the a3 chain of COL VI
(3168’KPGVISVMGT’3177). The antibody was
found to be specific to the target sequence when
tested against the elongated and truncated pep-
tide, published by Sun et al in 2015 [11]. The assay
has an intravariation of 6.8 % and an intervariation
of 9.2%. It has been approved for up to four freeze-
thaw cycles and storage of serum and EDTA
plasma samples up to 48 H at 4°C and 20°C as
reported previously [11]. The assay was carried out
as previously described [11].
Statistical analysis
Baseline characteristics are described as median
and interquartile range (IQR; 25th percentile to
75th percentile) for continuous variables and num-
ber (percentages) for categorical variables. Contin-
uous variables were not normally distributed and
are therefore presented as median with IQR. Cor-
relations between PRO-C6 levels and continuous
variables were performed using Spearman correla-
tions. Statistical significance was set at p < 0.05.
Mann–Whitney U-test was used for two-group
comparison of PRO-C6 levels. Survival analysis
with Kaplan–Meier curves and log-rank tests were
performed for PRO-C6 levels divided into tertiles
(high, medium and low levels) in the discovery
cohort. Cox proportional hazard regression analy-
sis (hazard ratios (HR) with 95% confidence inter-
val, (CI)) was used in the discovery cohort and
binary logistic regression (OR with 95% CI) in the
validation cohort. Two different regression analy-
ses were used as not all European sites in the
validation cohort (IMI-SUMMIT) had access to
equally detailed follow-up time with the exact date
of events. Follow-up analysis was performed
regarding three end-points: 1) cardiovascular
events, 2) cardiovascular death and 3) all-cause
death. The description of the models A, B and C
and their creations can be found in the online
supplemental material. For statistical analysis,
IBM SPSS version 24 was used. Box plots and
Kaplan–Meier curves were made using GraphPad
Prism version 7.05 (GraphPad Software Inc, CA,
USA).
Results
PRO-C6 is expressed in human atherosclerotic plaques
PRO-C6 was expressed in advanced human
atherosclerotic plaques and was localized in the
core as well as in areas close to the core and in the
shoulder regions of the plaque (Fig. 2).
PRO-C6 levels and the baseline characteristics of the discovery cohort
(CPIP)
The baseline characteristics of the discovery cohort
are shown in Table 1. The median plasma level of
PRO-C6 in the discovery cohort was 7.9 ng/ml
(IQR, 5.4–10.3).
PRO-C6 levels correlate with age, BMI, CRP and creatinine in the
discovery cohort (CPIP)
We tested the association of PRO-C6 levels to risk
factors and clinical characteristics in the discovery
cohort, particularly considering that PRO-C6 has
previously been linked to progression to end-stage
renal disease [12, 13]. Levels of PRO-C6 correlated
with age (p < 0.001), BMI (p=<0.05), creatinine
(p=<0.001) and hs-CRP (p=<0.01, Table 2).
PRO-C6 is elevated in patients with preoperative symptoms, diabetes,
hypertension, obesity and smoking in the discovery cohort (CPIP)
PRO-C6 levels in patients who had experienced
cerebrovascular symptoms preoperatively were sig-
nificantly higher when compared to those from
asymptomatic patients (median (IQR) 8.03 (5.52–
10.57) vs 6.84 (4.37–8.64) ng/ml; p = 0.001; Fig. 3).
Patients with diabetes had higher levels of PRO-C6
comparedwithpatientswithoutdiabetes (9.30 (6.31–
11.87) vs 7.53 (5.23–9.86) ng/ml; p < 0.001). In
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patients with hypertension, levels of PRO-C6 were
higher comparedwith patientswithout hypertension
(8.24 (5.53–10.67) vs 7.10 (4.69–8.99) ng/ml;
p < 0.001) and obese patient had higher levels com-
pared with nonobese patients (8.27 (5.84–10.48) vs
7.20 (5.07–9.71) ng/ml;p < 0.01). Patientswhowere
current smokers had lower levels of PRO-C6 com-
pared with nonsmokers (7.49 (5.04–9.79) vs 8.16
(5.51–10.57) ng/mL; p < 0.05).
Patients with high levels of PRO-C6 have an increased risk of all-
cause and cardiovascular death in the discovery cohort (CPIP)
Median follow-up time for cardiovascular events
was 38 months (IQR: 15–59) and 43 months (IQR:
21–65) for death. A total of 77 (17.8%) patients
suffered a cardiovascular event, 31 (7.2%) patients
died of cardiovascular disease, and 54 (12.5%)
patients died of all-cause death. Patients in the
highest tertile of PRO-C6 had a higher risk of future
cardiovascular death as well as all-cause death
compared with the low and medium tertiles com-
bined (Figure S1, log-rank test p = 0.020 and
p < 0.001, respectively). However, there was no
significant association with future cardiovascular
events (log-rank test p = 0.23).
In a Cox proportional hazard regression model,
levels of PRO-C6 predicted future cardiovascular
events (HR 1.089 [95% CI 1.019 1.164], p = 0.01),
cardiovascular death (HR 1.118 [95% CI 1.008
1.241], p = 0.04) and all-cause death (HR 1.087
[95%CI 1.0081.172],p = 0.03) after correcting for
potential confounders (age, gender, diabetes, hyper-
tension, obesity, smoking, preoperative symptoms,
creatinine, hs-CRP, HDL; Table S1).
PRO-C6 levels correlate with established cardiovascular risk factors
in the validation cohort (IMI-SUMMIT)
PRO-C6 values in the validation cohort correlated
with age (r = 0.181, p < 0.001), waist (p < 0.001),
BMI (p < 0.001) and inversely to height (p < 0.01).
Levels of PRO-C6 were also correlated to creatinine
(p < 0.001), HbA1c (p < 0.001) and hs-CRP
(p < 0.001) (Table 2).
PRO-C6 levels were elevated in patients with dia-
betes compared with patients without diabetes
with a median (IQR) 9.3 (7.4–12.0) vs 8.40 (6.80
vs 10.4) ng/ml, p < 0.001 (Fig. 3). Levels of PRO-
C6 were higher in patients with hypertension
compared with patients without hypertension
median (IQR) 9.20 (7.30–11.6) vs 8.5 (7.0–10.9)
ng/ml, p < 0.01, and obese patients (patients with
BMI 30 and above) had higher levels compared
with nonobese patients 9.4 (7.4–11.8) vs 8.6 (7.1–
11.1) ng/ml, p = 0.001.
PRO-C6 levels predict cardiovascular events in the validation cohort
(IMI-SUMMIT)
A total of 42 patients (3.2%) died during the 3-year
follow-up time, and of those, 13 patients (31%) died
Fig. 2 Histological staining of PRO-C6 in human carotid artery plaque. Brown areas represent immunohistochemistry
stainings of PRO-C6 (left) and staining with an isotype control in matching concentration (right) in a representative advanced
atherosclerotic plaque, showing that PRO-C6 is expressed mostly in the shoulder region and in and around the core.
Squares shown in bottom at x2 magnification. Bar represents 200 lm.
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of cardiovascular causes. A total of 145 (11%)
patients suffered from fatal or nonfatal cardiovas-
cular events during the three-year follow-up
period.
The levels of PRO-C6 predicted future cardiovas-
cular events (OR 1.063 [95% CI 1.011 1.117],
p = 0.017) in a binary logistic regression model
which was corrected for potential confounders
(age, gender diabetes, hypertension, obesity, smok-
ing, preoperative symptoms creatinine, hs-CRP,
HDL; Table S2). The levels of PRO-C6 did not
predict cardiovascular death but did predict all-
cause death. However, the significance was lost in
the last step of correction for confounders.
Discussion
In this study, we measured a marker of collagen VI
formation (PRO-C6) in subjects with a high preva-
lence of atherosclerosis from centres across Eur-
ope. PRO-C6 levels in the blood correlated with
higher BMI, creatine and CRP and were associated
with a higher risk of future cardiovascular events
in both the discovery and validation cohort after
correcting for potential confounders. PRO-C6 was
associated with a higher risk of cardiovascular and
all-cause death in the discovery cohort. Interest-
ingly, PRO-C6 was present both in the core area
and in the shoulder region of atherosclerotic
plaques.
To our knowledge, this is the first study showing
that a marker of collagen type VI formation is
located in human atherosclerotic plaques and that
circulating levels of this marker are able to predict
future cardiovascular events, cardiovascular death
and all-cause death.
Noninvasive biomarkers that reflect plaque vulner-
ability are needed and collagen markers may be an
attractive possibility. Collagens are a major con-
stituent of the atherosclerotic plaque, but most
research has focused on collagen type I [14–16].
Nevertheless, there has recently been an increasing
interest in collagen type VI in various tissues and
diseases [6,8,17].
Endotrophin is a cleavage fragment of collagen type
VI alpha-3 chain. Since endotrophin is part of the
C-terminal propeptide of collagen type VI, the PRO-
C6 assay, detecting the ten last amino acids of the
alpha-3 chain may be used to measure endotro-
phin as well.
Endotrophin is a matrikine that can amplify
fibrotic processes, and by amplifying contribute to
a thicker cap and a more stable plaque phenotype
[8, 12, 18, 19]. Nevertheless, collagen type VI
Table 2 Spearman correlations for clinical characteristics
and clinical blood samples and PRO-C6 values for 577
patients in the discovery cohort (CPIP) in blue and PRO-C6
values for 1378 patients in the validation cohort (IMI-
SUMMIT) in black
Discovery cohort (CPIP)
p-valueClinical characteristics Spearman’s rho
Age r = 0.312 1.78 9 1014
Waist r = 0.155 8.6 9 104
Height r = 0.042 ns
Weight r = 0.057 ns
BMI r = 0.104 0.013
Clinical blood measurements
Creatinine r = 0.285 3.60 9 1012
CRP r = 0.146 5.2 9 104
Total cholesterol r = 0.006 ns
Triglycerides r = 0.076 ns
LDL r = 0.009 ns
HDL r = 0.039 ns
HbA1ca r = 0.015 ns
Validation cohort (IMI-SUMMIT)
p-valueClinical characteristics Spearman’s rho
Age r = 0.181 1.35 9 1011
Waist r = 0.130 2.0 9 106
Height r = 0.130 ns
Weight r = 0.086 0.001
BMI r = 0.114 2.5 9 105
Clinical blood measurements
Creatinine r = 0.273 2.58 9 1024
CRP r = 0.137 3.88 9 107
Total cholesterol r = 0.046 ns
Triglycerides r = 0.061 0.025
LDL r = 0.038 ns
HDL r = 0.092 6.6 9 104
HbA1ca r = 0.110 5.2 9 105
Abbreviations: BMI, body mass index; CRP, C-reactive
protein; HbA1c, haemoglobin A1c; HDL, high-density
lipoprotein; LDL, low-density lipoprotein; Ns, not signif-
icant.
aHbA1c only for subjects with diabetes in CPIP.
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Fig. 3 Boxplots illustrating differences in levels of PRO-C6 in patients with preoperative symptoms/previous cardiovas-
cular disease, diabetes, hypertension current smoking, obsess patients and statin treatment in the discovery cohort (CPIP
and validation cohort (IMI-SUMMIT).). Boxes represent interquartile range (IQR) and whiskers represent 1.5 IQR and dots
indicate outliers. Ns = p > 0.05, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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synthesis has showed to be driven by the platelet-
associated platelet-derived growth factor (PDGF)
[20, 21]. Platelets are important contributors to
plaque inflammation, and their aggregation to the
endothelial surface and activation could be asso-
ciated with both atherosclerotic plaque formation,
as well as acute thrombotic events [22]. Increased
levels of released endotrophin could therefore be
associated with an increased endothelial platelet
aggregation. Other matrikines have previously
been described as proteolytically released bioactive
ECM fragments [23]. One example of this is Tum-
statin, which is an MMP-9-derived fragment from
the alpha-3 chain of collagen type IV known to
inhibit angiogenesis [23]. This suggests that ECM-
generated matrikines, such as endotrophin, may
have a biological role in ECM remodelling, poten-
tially affecting plaque vulnerability [10].
PRO-C6 levels were higher in subjects with dia-
betes compared with nondiabetics: PRO-C6 has
previously been identified as a predictive biomar-
ker of treatment response in type 2 diabetes [21].
Moreover, PRO-C6 has also previously been shown
to be a marker for all-cause mortality in patients
with type 1 and type 2 diabetes with kidney
damage, and in patients with chronic kidney
disease [13, 17, 21].
In thediscovery andvalidation cohort, levels of PRO-
C6 correlated with age and increased creatinine,
indicating that collagen VI formationmight increase
with age and worsened kidney function. The corre-
lations seen in both cohorts between levels of PRO-
C6 and markers of metabolic dysfunction, BMI,
waist and CRP further strengthen the hypothesis
that the PRO-C6 also reflects the matrikine endo-
trophin, as endotrophin was previously found to be
associated to adipose tissue fibrosis, insurgence of
insulin resistance and recruitment of inflammatory
cells [21, 24]. The lower levels of PRO-C6 found in
current smokers in the discovery cohort were unex-
pected, however may partly be explained by current
smokers in the cohort having a lower weight com-
pared with the nonsmokers (median 75 [IQR 65–87]
vs 79 [IQR 69–88] kg, p = 0.041). Next to smoking,
lower PRO-C6 levels in the discovery compared with
the validation cohort could be due to the higher BMI
and waist circumference observed, since endotro-
phin previously has been associated with adipose
tissue fibrosis [8, 24]. The two cohorts in this study
have differences in the prevalence of risk factors.
There was a lower cardiovascular event rate (11.0 %
vs17.8%), cardiovascular death rate (1.0%vs7.2%)
and all-cause death rate (3.2 % vs 12.5%) in the
validation cohort compared with the discovery
cohort. The validation cohort studywas particularly
designed to discover new markers for cardiovascu-
lar disease in subjectswith diabetes, which explains
the larger percentage of patients with diabetes and
consequently the higher weight, waist circumfer-
ence, BMI andHb1Ac found in the validation cohort.
The fact that both cohorts include patients with
atherosclerosis, but have differences in their partic-
ipants, makes them complementary in the evalua-
tion of PRO-C6 as a clinical biomarker.
Nevertheless, since PRO-C6 was associated with a
higher risk for all-cause death in both cohorts it
seems that PRO-C6 not only reflects risk for
cardiovascular events, but may also reflect other
pathological processes that affect the ECM, such
as diseases with high tissue turnover13,21,25,26.
Study limitations
PRO-C6 was detected in the human atherosclerotic
plaques, indicating that PRO-C6 levels in the blood
might partly stem from the atherosclerotic plaques
in the vasculature. However, the proportion of PRO-
C6 originating from other tissues, such as the
adipose tissue, has not been investigated in this
study. Furthermore, since this is a prospective
study there is a lack of definite proof for causality
between levels of PRO-C6, plaque vulnerability and
future cardiovascular events. However, the finding
that PRO-C6 is associatedwith future events in both
these two large prospective cohorts shows that PRO-
C6 isapotentialmarker to stratifypatientsat risk for
cardiovascular events in a clinical setting. Another
limitation is the lack of healthy controls for PRO-C6
immunohistochemistry; however, this was not pos-
sible to obtain for this study.
Conclusion
This study shows that PRO-C6 correlates with
markers of metabolic dysfunction and cardiovas-
cular risk factors and that PRO-C6 levels are
associated with future cardiovascular events, car-
diovascular death and all-cause death in two
different large prospective cohorts.
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